Back to results
US 2026/0137773 A1Published application
Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
AssigneeViroMissile, Inc.
InventorNanhai George CHEN
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeViroMissile, Inc.
InventorNanhai George CHEN
Estimating the term…
Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and/or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus strains that include an inactivating mutation in one or more viral genes, and/or one of more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses, e.g., vaccinia viruses, provided herein, including recombinant vaccinia viruses, can be used as an oncolytic virus therapy, e.g., an oncolytic vaccinia virus therapy, for treating cancer. Also provided herein are pharmaceutical compositions and methods and uses of the viruses, e.g., vaccinia viruses, for treating cancer, as well as nucleic acids encoding the viruses.
A recombinant vaccinia virus, comprising a heterologous nucleic acid encoding an inducible apoptosis protein, wherein the apoptosis protein is a death effector domain of the Fas-associated death domain-containing protein (DED), a Fas, or a caspase.
A recombinant vaccinia virus, comprising a heterologous nucleic acid encoding an inducible death effector domain (iDED), wherein the iDED comprises a death effector domain (DED) of the Fas-associated death domain-containing protein (FADD) fused with an FKBP variant that is able to bind AP1903 (Rimiducid).
A recombinant vaccinia virus derived from Vaccinia IHD-J strain genome, comprising a heterologous nucleic acid encoding an inducible death effector domain (iDED), wherein the iDED comprises a death effector domain (DED) of the Fas-associated death domain-containing protein (FADD) fused with an FKBP variant that is able to bind AP1903 (Rimiducid), the heterologous nucleic acid is inserted into the genome of the vaccinia virus at the J2R gene locus, and the nucleic acid genome of the recombinant oncolytic vaccinia virus has at least 95% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:
A recombinant vaccinia virus comprising a nucleic acid genome that has at least 95% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:
Dependencies are inferred from the claim text.